Transformational Dry Eye Therapy

Episodic Care

Continuity of Care

Barry J. Linder, MD, MS
President & CEO
Eyedetec Medical, Inc.

Understanding Dry Eye Disease (DED)

"85% of patients who have DED do not have a lack of tears, they have MGD (Meibomian Gland Dysfunction). And MGD is treatable. That means we have been treating 85% of patients wrong for 50 years!!!"
Daniel Durrie, MD

DED Impacts Quality of Life & Vision, and is a Global Eye Health Challenge

Key Challenges in DED – The Problems

Transformational Solution

Transformational Solution – Novel Technology

Eye Lipid Mobilizer™ (ELM)

Treatment of Moderate to Severe DED
Continuity of care from Practice to Home
Telehealth Enabled
Patented Mechanisms of Action

Scalable Continuity of Care

Cost Effective
Efficient to Meet Growing Demand

Global Market Approaching $7.8 Billion by 2026 (350M Patients)

Eyedetec will Initially Focus on USA Market of $2.4B (30M Patients) – Growing 6.9% CAGR

eyedetec cataract

REFRACTIVE
CATARACT SURGERY

$4B Global Intraocular Lens Market Excellent Refractive Cataract Outcomes Depend on Treating DED

CONTACT LENS
INTOLERANCE 38%

$14B Global Contact Lens Market

INCREASED INCIDENCE
WITH AGING POPULATION

25% of Population >50 y.o.

SCREEN TIME &
DECREASED BLINKING

Coming DED tsunami!

Excellent Refractive Cataract Outcomes Depend on Treating DED

Coming DED tsunami!

Eyedetec Understands the DED Market

EyeGiene® Insta-Warmth™

Treatment of Mild DED
- Reusable Eye Mask
- Disposable Warming Wafers
- Controlled Heat
Clinical validation (Singapore Eye Research Institute)
US FDA Class I Exempt
Sales (USA & OUS)
- Online
- 12 International Distributors

Attractive Value Proposition

Win, Win for both Doctor and patient

Patient

Affordable
Automated
Relaxing
Convenient Home Care Solution
Connectivity to doctor

Ophthalmologists & Optometrist

Least capital intensive option
Differentiated technology
Digital Telehealth solution
New way to serve customers
Recurring revenue stream

Why Invest in the Future of Dry Eye care?

Management Team

Barry J Linder, MD, MS President & CEO

Thomas Dunlap
Global Business Advisor

Shareef Mahdavi Strategic Marketing

Anselm Leung Financial Advisor

James Dippo R&D

John Kang RQ&C

Ronald Linder Operations

Scientific Advisory Board

Daniel Durrie, MD

Randall Fuerst, OD

John Hovanesian, MD

Paul Karpecki, OD

Leslie O'Dell, OD

Laura Periman, MD

John Sheppard, MD

Vance Thompson, MD